Management of the adverse effects of lenalidomide in multiple myeloma

Advances in Therapy

Volumn 28, Issue SUPPL. 1, 2011, Pages 1-10

  Rodríguez, Ana Pilar González ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Adverse effects; Lenalidomide; Multiple myeloma

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; COTRIMOXAZOLE; DEXAMETHASONE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ANEMIA; ASTHENIA; ATROPHIC SKIN DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CONSERVATIVE TREATMENT; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FEBRILE NEUTROPENIA; FLUID INTAKE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY FUNCTION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PRACTICE GUIDELINE; REVIEW; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; GASTROINTESTINAL DISEASE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL DISEASES; HUMANS; INFECTION; MULTIPLE MYELOMA; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 79955653200     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0104-8     Document Type: Review

References (41)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
2. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006;42:1671-1683. (Pubitemid 44118778)
3. Gay F, Palumbo A. Multiple myeloma: management of adverse events. Med Oncol. 2010;27:646-653.
4. Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
5. Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
6. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164-170.
7. Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82:426-432.
8. Ishak J, Dimopoulus MA, Weber D, Knight RD, Shearer A, Caro J. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood (ASH Annual Meeting abstracts). 2008;112:3708.
9. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME. Eastern Cooperative Oncology Group. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an openlabel randomised controlled trial. Lancet Oncol. 2010;11:29-37.
10. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766-1771. (Pubitemid 44884050)
11. Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137-4143.
12. Palumbo A, Falco P, Corradini P, et al. GIMEMA-Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459-4465 (Pubitemid 350063804)
13. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111:1101-1109. (Pubitemid 351213388)
14. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050-4503.
15. Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood (ASH Annual Meeting abstracts). 2006;108:3554.
16. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function: Cancer. 2010;116:3807-3814.
17. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia/ trompocytopenia and time to event results. Haematologica. 2008;93(suppl. 1):96
18. Reece D, Masih-Khan, Chen C, et al. Lenalidomide (Revlimid) ±costicosteroid in elderly patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting abstracts). 2006;108:3550.
19. Blade J. Complications of multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1231-1246. (Pubitemid 350051348)
20. Palumbo A, Rajkumar SV, Dimopoulus MA, et al. International Myeloma Working Group. Prevention of thalidomide and lenalidomide associated trombosis in myeloma. Leukemia. 2008;22:414-423.
21. Weber D, Rankin K, Gavion M, Dalasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
22. Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survivel in relapsed multiple myeloma. Clin Cancer Res. 2002;8:3377-3382. (Pubitemid 35340711)
23. Zangari M, Anaissie E, Barlogi B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
24. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991-4998.
25. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006;134:399-405. (Pubitemid 44079553)
26. Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide associated venous thromboembolism. Blood Coagul Fibrinol. 2009;20:3377-3339.
27. Brandenburg NA, Goss TF, Knight T, Xu X, Knight RD. Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens. Blood (ASH Annual Meeting abstracts). 2008;112:2369.
28. Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010;116:22-26.
29. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009;114:772-778.
30. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067. (Pubitemid 35217050)
31. Zangari M, Tricot G, Zeldis J, Eddelmon P, Saghafifar F, Barlogi B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapsed after high dose of chemotherapy. Blood (ASH Annual Meeting abstract ). 2001:98:3225.
32. Zonder JA, Barlogie B, Durie DG, Mc Coy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood (ASH Annual Meeting abstracts). 2006;108:403. (Pubitemid 43990659)
33. Knight T, DeLap RJ, Zeldis JB. Lenalidomide and venous trombosis in multiple myeloma. N Engl J Med. 2006;354:2079-2080.
34. Zangari M, Tricot G, Poavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone. J Clin Oncol. 2009;28:132-135.
35. Wright JA, Weber D, Thomas SK, et al. Characteristics of patients experiencing thomboembolic events during treatment for multiple myeloma: asprin may not be adecuate thromboprofilaxis in patients with multiple risk factors. Blood (ASH Annual Meeting abstracts). 2007;110:1882.
36. Klein U, Kosely F, Hillegab J, et al. Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol. 2009;88:67-71.
37. Palumbo A, Dimopoulus M, San Miguel J, Harousseau JL, Attal M, Hussein M. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Reviews. 2009;23:87-93.
38. Weber DM, Spencer A, Wang M, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma with impaired renal function. J Clin Oncol (Annual Meeting of American Society of Clinical Oncology abstracts). 2008;26:8542.
39. Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J. Lenalidomideinduced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007;138:640-643. (Pubitemid 47206719)
40. Simpson I, Rajkumar SV. Dispenzieri A. High incidente of diarrhea in patients on long term teraphy with lenalidomide and dexamethasone for multiple myeloma. J Clin Oncol. 2008;26:8586.
41. Kumar S, Giralt S, Stadmauer EA. Mobilization in myeloma revisited: IMWG consensus perspectiveson stem cell collection following inicial therapy with thalidomide-, lenalidomideor bortezomib containing regimens. Blood. 2009:114;1729-1735.